Physician profile
Halee Walden
NPI 1083310460
$1,400.80
in general payments reported to CMS, 2019-2025
13 companies · $782 in 2025
The $782 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $203 · 2024: $416 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.80 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $300.95 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $242.34 | 2024-2025 | |
| Sage Therapeutics, LLC | $181.85 | 2024-2025 | Zurzuvae |
| Novo Nordisk INC | $146.56 | 2023-2024 | Wegovy |
| Sumitomo Pharma America, INC. | $132.79 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $100.31 | 2024-2025 | Slynd |
| Millicent US INC | $99.54 | 2024-2025 | Femlyv, Intrarosa |
| Pfizer INC. | $81.07 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.94 | 2023-2025 | |
| Shield Therapeutics INC | $21.53 | 2025 | |
| Supernus Pharmaceuticals, INC. | $15.40 | 2025 | Qelbree |
| Abbvie INC. | $13.58 | 2023 | |
| Organon LLC | $11.94 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halee Walden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.